Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
ReNeuron : Appointments to Scientific Advisory Board
share with twitter share with LinkedIn share with facebook share via e-mail
0
08/22/2019 | 08:44am EDT
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, today announces the appointment of Professor Robert MacLaren, Dr Sally Temple and Dr Jose-Alain Sahel to its Scientific Advisory Board.
Professor Robert MacLaren is Professor of Ophthalmology at the University of Oxford, where he directs research into developing new clinical treatments for blindness, using stem cells, gene therapy and electronic retinal implants. In 2016 he performed the world's first operation inside the human eye using a remotely controlled robot. Together with the University of Oxford, in 2014 he co-founded Nightstar Therapeutics, a biotechnology company originally based at the Wellcome Trust in London, to develop gene therapy treatments for patients with retinal diseases. Nightstar was acquired for $800 million by Nasdaq-listed Biogen, Inc. in June 2019.
Dr Sally Temple is the Scientific Director of the Neural Stem Cell Institute in New York. She leads a team of 30 researchers focused on using neural stem cells to develop therapies for eye, brain, and spinal cord disorders. In 1989, she discovered that the embryonic mammalian brain contained a rare stem cell that could be activated to proliferate in vitro and produce both neurons and glia. Since then, her team has continued to make pioneering contributions to the field of stem cell research. Their research on the characterisation of neural stem and progenitors brings closer the prospect of effective clinical treatments for central nervous system damage in which tissue is lost, for example, due to neurodegenerative diseases or trauma.
Dr Jose-Alain Sahel is the chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, of the UPMC Eye Center, and the Eye and Ear Foundation Endowed Chair of Ophthalmology. He founded and still heads the Institut de la Vision (Sorbonne Universite-Inserm-CNRS) in Paris, one of the largest Vision Research Centres worldwide. Dr Sahel is known worldwide for his expertise in vision restoration techniques. He has led pioneering efforts in neuroprotection, prosthetic and optogenetic vision restoration, a technique in which cells in the retina are genetically modified to express light sensitive proteins. Dr Sahel founded Fovea Pharmaceuticals, which later became the Ophthalmology Division of Sanofi Aventis. He is also a scientific co-founder of GenSight Biologics, Pixium Vision and Sparing Vision. He is a member of the French and German National Academies of Science.
ReNeuron'sScientific Advisory Board is composed of leading academics and industry executives with a world-class breadth of expertise across the Company's areas of operation. Its role is to advise the Company on scientific matters relating to its research and clinical development strategy. This includes the future direction of cell therapy, links to academic, regulatory and industrial organisations and relationships with peer companies and government bodies on a global basis.
Olav Hellebo, Chief Executive Officer of ReNeuron, commented: 'We are delighted to welcome these renowned experts to our Scientific Advisory Board. They will provide invaluable insight and counsel across ReNeuron's therapeutic programmes as we progress our pioneering therapies towards commercialisation.'
Contact:
Tel: +44 (0)20 3819 8400
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell technologies to develop 'off the shelf' stem cell treatments, without the need for immunosuppressive drugs. The Company's lead clinical-stage candidates are in development for the blindness-causing disease, retinitis pigmentosa, and for disability as a result of stroke. ReNeuron is also advancing its proprietary exosome technology platform as a potential delivery system for drugs that would otherwise be unable to reach their site of action. ReNeuron's shares are traded on the London AIM market under the symbol RENE.L.
https://www.marketscreener.com/RENEURON-GROUP-PLC-4005458/news/ReNeuron-Appointments-to-Scientific-Advisory-Board-29101004/
Edited Transcript of RENE.L earnings conference call or presentation 11-Jul-19 9:00am GMT
https://finance.yahoo.com/news/edited-transcript-rene-l-earnings-201732604.html
Good luck and GOD bless,
Well that was an anti-climax.
There was no new interesting information from the call than wasn't able to be gleaned from the corporate presentation that was already available.
Great results so far though, and looking to October to see the real value of the company
Sold RNUGF shares today to buy more AVXL shares.
I still love Reneuron but I believe that SOON AVXL shares could increase faster.
Good luck and GOD bless,
NEWS!!!
http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/RENE-2019-preliminary-results-FINAL.pdf
Good luck and GOD bless,
Will there be more buying of this stock today or tomorrow???
Webcast of Preliminary Results
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of
cell-based therapeutics, will webcast the analyst briefing on the day of its
preliminary results, Thursday 11 July 2019.
To listen to the webcast live, please log on to the following web address
approximately 5 minutes before 10.00am BST on the day of results:
https://webcasting.buchanan.uk.com/broadcast/5d011332221579216107d918
A recording of the webcast will later be made available at ReNeuron’s website,
www.reneuron.com.
The analyst briefing will be held at 10.00am BST on 11 July 2019 at the offices of
Buchanan, 107 Cheapside, London EC2V 6DN.
For more information, please contact Buchanan on reneuron@buchanan.uk.com
or 020 7466 5000.
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK) +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Argot Partners (US)
Stephanie Marks, Claudia Styslinger
Stifel Nicolaus Europe Limited
+1 212 600 1902
+44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison
(NOMAD and Joint Broker)
http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/ReNeuron-Results-webcast-RNS-FINAL.pdf
NEWS on Thursday July 11, 2019
For more information, please contact Buchanan on reneuron@buchanan.uk.com
or 020 7466 5000.
http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/ReNeuron-Results-webcast-RNS-FINAL.pdf
Good luck and GOD bless,
No news. No insider buys. No instit buyers?
Just 7 calendar days from NEWS on Thursday July 11, 2019
http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/ReNeuron-Results-webcast-RNS-FINAL.pdf
Good luck and GOD bless,
NEWS within 2 weeks from TODAY June 27, 2019
Target is five, but who knows. Got sell for nine.
ReNeuron wins Breakthrough of the Year Award
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based
therapeutics, is delighted to announce that it has won the ‘Breakthrough of the Year’ award at
last night’s 2019 European Mediscience Awards in London.
This award underlines the strong clinical development and commercial progress ReNeuron has
made over the past year. This includes positive data from the ongoing Phase 1/2a clinical trial
in Retinitis Pigmentosa and the signing of an exclusive licence agreement with Shanghai Fosun
Pharmaceutical Industrial Development Co., Ltd. for the development, manufacture and
commercialisation of ReNeuron’s CTX and hRPC cell therapy programmes in the People’s
Republic of China.
Olav Hellebø, Chief Executive Officer of ReNeuron, commented:
“We are delighted to have been awarded the Breakthrough of the Year award at the 2019
European Mediscience Awards. We are greatly encouraged by the progress we have made with
our cell therapy clinical development programmes for retinitis pigmentosa and stroke disability
over the past year and look forward to continuing to advance our clinical and business
development activities in the months ahead.”
The European Mediscience Awards is one of the largest annual gathering of private and publicly
quoted healthcare, biotech and life sciences companies in Europe. It celebrates the best in the
sector and highlights the achievements of individuals and companies operating within it.
ENDS
Contacts:
ReNeuron +44 (0) 20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK Media/Investor Relations) +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Argot Partners (US Media/Investor Relations) +1 212 600 1902
Stephanie Marks, Claudia Styslinger
Stifel Nicolaus Europe Limited (NOMAD and Joint Broker)
Jonathan Senior, Stewart Wallace, Ben Maddison
+44 (0) 20 7710 7600
N+1 Singer (Joint Broker)
Aubrey Powell, Mark Taylor
+44 (0) 20 7496 3000
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem cell
technologies to develop ‘off-the-shelf’ stem cell treatments, without the need for
immunosuppressive drugs. The Company’s lead clinical-stage candidates are in
development for the blindness-causing disease, retinitis pigmentosa and for disability
as a result of stroke. ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that would otherwise be unable to
reach their site of action. ReNeuron’s shares are traded on the London AIM market
under the symbol RENE.L. Further information on ReNeuron and its products can be
found at www.reneuron.com.
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of
cell-based therapeutics, will webcast the analyst briefing on the day of its
preliminary results, Thursday 11 July 2019.
To listen to the webcast live, please log on to the following web address
approximately 5 minutes before 10.00am BST on the day of results:
https://webcasting.buchanan.uk.com/broadcast/5d011332221579216107d918
A recording of the webcast will later be made available at ReNeuron’s website,
www.reneuron.com.
The analyst briefing will be held at 10.00am BST on 11 July 2019 at the offices of
Buchanan, 107 Cheapside, London EC2V 6DN.
For more information, please contact Buchanan on reneuron@buchanan.uk.com
or 020 7466 5000.
ENDS
ENQUIRIES:
ReNeuron +44 (0)20 3819 8400
Olav Hellebø, Chief Executive Officer
Michael Hunt, Chief Financial Officer
Buchanan (UK) +44 (0) 20 7466 5000
Mark Court, Sophie Wills, Tilly Abraham
Argot Partners (US)
Stephanie Marks, Claudia Styslinger
Stifel Nicolaus Europe Limited
+1 212 600 1902
+44 (0) 20 7710 7600
Jonathan Senior, Stewart Wallace, Ben Maddison
(NOMAD and Joint Broker)
Nplus1 Singer Advisory LLP +44 (0) 20 7496 3000
Aubrey Powell, Mark Taylor (Joint Broker)
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics, harnessing its unique stem
cell technologies to develop ‘off the shelf’ stem cell treatments, without the need
for immunosuppressive drugs. The Company’s lead clinical-stage candidates are in
development for the blindness-causing disease, retinitis pigmentosa, and for
disability as a result of stroke. ReNeuron is also advancing its proprietary exosome
technology platform as a potential delivery system for drugs that would otherwise
be unable to reach their site of action. ReNeuron’s shares are traded on the
London AIM market under the symbol RENE.L. For further information visit
www.reneuron.com.
ReNeuron Group (RNUGF) Lifted to “Buy” at Zacks Investment Research
https://mayfieldrecorder.com/2019/06/07/reneuron-group-rnugf-lifted-to-buy-at-zacks-investment-research.html
Good luck and GOD bless,
A video from 2017 with good descriptions of the current pipeline of therapies in currently in clinical trials for ReNeuron
ReNeuron Group plc
(“ReNeuron” or the “Company”)
Jefferies 2019 Global Healthcare Conference
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the development of cell-based therapeutics, is pleased to announce that the Company’s management team will be participating in 1-on-1 meetings at the Jefferies 2019 Global Healthcare Conference on Tuesday 4 June 2019 in New York City.
http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/ReNeuron-Jefferies-Global-Healthcare-Conference-2019.pdf
Good luck and GOD bless,
I expect $10.00 or more per share before the end of this year and probably before the end of the third quarter of the calendar year on September 30, 2019.
Good luck and GOD bless,
Major Shareholdings:
The current issued share capital of the Company, including shares issued under its blocklisting facility, is 31,799,617 ordinary shares. No shares are held as treasury.
The Directors (together with their families and their family trusts and pension scheme arrangements) in aggregate hold 418,575 ordinary shares in the Company, representing 1.32% of the Company’s current issued share capital. 36.53% of the issued share capital is not in public hands.
The Company is aware of the following significant (3% or greater) shareholdings in the Company’s ordinary shares:
Number of ordinary shares % of issued share capital
Woodford Investment Management Limited 35.39%
Arthurian Life Sciences SPV GP Ltd, as GP of The Wales Life Sciences Investment Fund LP 9.48%
The above information was last updated on Friday, 10 May 2019
http://www.reneuron.com/investors/major-shareholdings/
Good luck and GOD bless,
Please feel free to alert me private if you see a new candidate! Have to accumulate some wealth to help a special person in need. If you wish of course.
Thanks for the welcome.
Take care! K
Just 10-11-12
WELCOME to this board.
I originally bought in here at $1.03 on March 12, 2019.
So far so good.
RNUGF is still under the radar here in the USA, but I expect that to change with more news regarding the retinitis pigmentosa trial results.
http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/ReNeuron-corporate-presentation-May-2019.pdf
Good luck and GOD bless,
https://www.edisongroup.com/publication/year-end-update-highlights-transaction-potential-2/24196
Good luck and GOD bless,
Going to need those to push it to ten.
ReNeuron Group primed for a pivotal 18 month
https://www.proactiveinvestors.co.uk/companies/news/219881/reneuron-group-primed-for-a-pivotal-18-months-219881.html
Good luck and GOD bless,
RNUGF stock price could easily exceed $10 per share before the end of July 2019 and easily exceed $30 per share by or before the end of 2019.
Good luck and GOD bless,
Latest presentation
http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/Jason-Commander-gene-stem-cell-conference-April-2019.pdf
Good luck and GOD bless,
ReNeuron is presenting at the following events.
Allogeneic Cell Therapies Summit
Start date: May 7, 2019
End date: May 9, 2019
Location: Boston, USA
http://www.reneuron.com/news/events/
Good luck and GOD bless,
ARVO 2019 Highlight: RP Patients in ReNeuron’s Cell Therapy Trial Show Further Vision Improvements
The latest ReNeuron results were presented at the sixth annual Retinal Cell and Gene Therapy Innovation Summit held on April 26 in Vancouver, Canada.
ReNeuron, a developer of cell-based therapies, has reported that the first three patients with retinitis pigmentosa (RP) in the Phase 2a cohort of its Phase 1/2 clinical trial have demonstrated sustained and further vision improvements since receiving the company’s human retinal progenitor cells (hRPC).
The hRPC are stem cells that have almost matured into photoreceptors, the retinal cells that make vision possible. The goal of the emerging treatment is to restore vision in people with RP and related conditions.
“The results for the ReNeuron trial continue to be promising. The improvements in visual acuity, which reflects the ability to perceive more detail and read smaller letters, are especially encouraging,” says Brian Mansfield, PhD, executive vice president of research and interim chief scientific officer at the Foundation Fighting Blindness. “We look forward to additional reports from the clinical study as it moves forward with more participants.”
The first subject in the Phase 2a cohort showed a 21-letter improvement (4 lines on an eye chart) in visual acuity at 120 days after receiving the treatment. Earlier, that subject had a 20-letter improvement at 60 days.
The second subject in the Phase 2a cohort showed a 25-letter improvement (5 lines on an eye chart) at 60 days after receiving the treatment. Earlier, that subject had a 15-letter improvement at 18 days.
The third subject in the Phase 2a cohort showed a 23-letter improvement (more than 4 lines on an eye chart) at 60 days after receiving the treatment. Earlier, that subject had a 14-letter improvement at 18 days.
Patients in the Phase 2a group had better vision at trial enrollment than those in the Phase 1 group. Those in Phase 1, which primarily focused on treatment safety, did not experience vision improvements.
The Foundation Fighting Blindness funded Michael Young, PhD, Massachusetts Eye and Ear, for pre-clinical and translational studies for the hRPC that helped make the ReNeuron trial possible.
The latest ReNeuron results were presented by Jason Comander, MD, PhD, a lead investigator for the trial at Massachusetts Eye and Ear, at the sixth annual Retinal Cell and Gene Therapy Innovation Summit on April 26. The summit, hosted by the Foundation Fighting Blindness and Casey Eye Institute, Oregon Health & Science University, preceded the 2019 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO) taking place in Vancouver, Canada, on April 28 – May 2.
https://www.fightingblindness.org/research/arvo-2019-highlight-rp-patients-in-reneuron-s-cell-therapy-trial-show-further-vision-improvements-14
Good luck and GOD bless,
ARVO 2019 Annual Meeting is Sunday April 28 - Thursday May 2
https://www.arvo.org/
The BIG DISCUSSIONS at ARVO:
Latest results show sustained and further improvement in vision at 60 and 120 days in first patient cohort of Phase 2a study of hRPC cell therapy in retinitis pigmentosa
http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/RENE-RP-clinical-update-26-April-2019-UK-RNS-FINAL.pdf
Good luck and GOD bless,
Reneuron
http://www.reneuron.com/
Good luck and GOD bless,
The Company is aware of the following significant (3% or greater) shareholdings in the Company’s ordinary shares:
Woodford Investment Management Limited 35.39%
Arthurian Life Sciences SPV GP Ltd, as GP of The Wales Life Sciences Investment Fund LP 9.48%
http://www.reneuron.com/investors/major-shareholdings/
Good luck and GOD bless,
https://portfolio-adviser.com/woodford-backed-stem-cell-company-rallies-520/
Good luck and GOD bless,
Reneuron has a trial for treating ischemic stroke patients
https://www.tvcommercialad.com/watch/9S7SqxHMMJw9c9s
Good luck and GOD bless,
ReNeuron Announces Presentation of Updated Efficacy and Safety Data from Retinitis Pigmentosa Study at the Sixth Annual Retinal Cell and Gene Therapy Innovation Summit
https://finance.yahoo.com/news/reneuron-announces-presentation-updated-efficacy-110000695.html
Good luck and GOD bless,
ReNeuron eye disease patients see “sustained and further improvement” in sight after cell treatment
https://www.proactiveinvestors.co.uk/companies/news/219157/reneuron-eye-disease-patients-see-sustained-and-further-improvement-in-sight-after-cell-treatment-219157.html
Good luck and GOD bless,
NEWS 4-26-2019
http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/RENE-RP-clinical-update-26-April-2019-UK-RNS-FINAL.pdf
Good luck and GOD bless,
By or before Friday April 26, 2019 NEWS!!! regarding (RNUGF) ReNeuron Group plc
https://www.proactiveinvestors.co.uk/companies/news/218786/ReNeuron-primed-for-further-progress--218786.html
http://4965zs3ha2l125fk78zkozo3.wpengine.netdna-cdn.com/wp-content/uploads/RENE-RP-clinical-update-FINAL.pdf
Good luck and GOD bless,
George
Sounds excellent George. I wish OXB could get some more of their pipeline licensed and progressed.
https://www.modernreaders.com/news/2019/04/19/reneuron-group-plc-rene-insider-buys-180000-in-stock.html
https://wallmine.com/otc/rnugf/officer/1141952/john-berriman
A total transaction of £180,000 ($235,201.88) is definitely a significant purchase at the market price.
Good luck and GOD bless,
Followers
|
0
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
63
|
Created
|
03/12/19
|
Type
|
Free
|
Moderators |
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |